News
12h
MedPage Today on MSNSGLT2 Inhibitor Shows Promise as MASH TreatmentCurrently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...
Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...
The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...
By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...
Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in confirmatory trials, with a lower dose of medication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results